Literature DB >> 29541759

Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.

Rebecca R Vanderpool1,2, Melissa Saul3, Mehdi Nouraie1,4, Mark T Gladwin1,4, Marc A Simon1,2,5,6.   

Abstract

Importance: Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, yet there are no specific therapies, possibly due to phenotypic heterogeneity. The development of pulmonary hypertension (PH) in patients with HFpEF is considered a high-risk phenotype in need of targeted therapies, but there have been limited hemodynamic and outcomes data. Objective: To identify the hemodynamic characteristics and outcomes of PH-HFpEF. Design, Setting, and Participants: Cohort study of participants who had a right heart catheterization from January 2005 to September 2012 (median [interquartile range] follow-up time, 1578 [554-2513] days) were analyzed. Hemodynamic catheterization data was linked to the clinical data repository of all inpatient and outpatient encounters across a health system. Single tertiary referral center for heart failure and PH within a large health care network using a common clinical data repository was studied. There were 19 262 procedures in 10 023 participants. Exposures: Participants were classified as having no PH, precapillary PH, or PH in the setting of left heart disease (reduced or preserved ejection fraction). Pulmonary hypertension associated with HFpEF was defined as mean pulmonary artery pressure of 25 mm Hg or more, pulmonary artery wedge pressure of 15 mm Hg or more, and left ventricular ejection fraction of 45% or more. Pulmonary hypertension severity was quantified by the hemodynamic parameters transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient. Main Outcomes and Measures: The primary outcome was time to all-cause mortality. Secondary outcomes were time to acute hospitalization and cardiovascular hospitalization.
Results: The mean (SD) of all study individuals was 65 (38) years. Of 10 023 individuals, 2587 (25.8%) had PH-HFpEF. Mortality was 23.6% at 1 year and 48.2% at 5 years. Cardiac hospitalizations occurred in 28.1% at 1 year and 47.4% at 5 years. The frequency of precapillary PH using clinically defined cut-offs for transpulmonary gradient (>12 mm Hg), pulmonary vascular resistance (3 Woods units), and diastolic pulmonary gradient (≥7 mm Hg) were 12.6%, 8.8%, and 3.5%, respectively. Transpulmonary gradient, pulmonary vascular resistance, and diastolic pressure gradient were predictive of mortality and cardiac hospitalizations. Conclusions and Relevance: In a large cohort referred for invasive hemodynamic assessment, PH-HFpEF was common. Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are all associated with mortality and cardiac hospitalizations.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29541759      PMCID: PMC5875307          DOI: 10.1001/jamacardio.2018.0128

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  42 in total

1.  Right ventricular function in heart failure with preserved ejection fraction: a community-based study.

Authors:  Selma F Mohammed; Imad Hussain; Omar F AbouEzzeddine; Omar F Abou Ezzeddine; Hiroyuki Takahama; Susan H Kwon; Paul Forfia; Véronique L Roger; Margaret M Redfield
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

2.  A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients.

Authors:  S Beddhu; F J Bruns; M Saul; P Seddon; M L Zeidel
Journal:  Am J Med       Date:  2000-06-01       Impact factor: 4.965

3.  Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

Authors:  Bradley A Maron; Edward Hess; Thomas M Maddox; Alexander R Opotowsky; Ryan J Tedford; Tim Lahm; Karen E Joynt; Daniel J Kass; Thomas Stephens; Maggie A Stanislawski; Erik R Swenson; Ronald H Goldstein; Jane A Leopold; Roham T Zamanian; Jean M Elwing; Mary E Plomondon; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Gaurav Choudhary
Journal:  Circulation       Date:  2016-02-12       Impact factor: 29.690

4.  The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease.

Authors:  Emmanouil Tampakakis; Peter J Leary; Van N Selby; Teresa De Marco; Thomas P Cappola; G Michael Felker; Stuart D Russell; Edward K Kasper; Ryan J Tedford
Journal:  JACC Heart Fail       Date:  2014-11-12       Impact factor: 12.035

5.  Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension.

Authors:  Christian Gerges; Mario Gerges; Marie B Lang; Yuhui Zhang; Johannes Jakowitsch; Peter Probst; Gerald Maurer; Irene M Lang
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

6.  Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.

Authors:  Christian F Opitz; Marius M Hoeper; J Simon R Gibbs; Harald Kaemmerer; Joanna Pepke-Zaba; J Gerry Coghlan; Laura Scelsi; Michele D'Alto; Karen M Olsson; Silvia Ulrich; Werner Scholtz; Uwe Schulz; Ekkehard Grünig; Carmine D Vizza; Gerd Staehler; Leonhard Bruch; Doerte Huscher; David Pittrow; Stephan Rosenkranz
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

7.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

8.  RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension.

Authors:  Rebecca R Vanderpool; Michael R Pinsky; Robert Naeije; Christopher Deible; Vijaya Kosaraju; Cheryl Bunner; Michael A Mathier; Joan Lacomis; Hunter C Champion; Marc A Simon
Journal:  Heart       Date:  2014-09-11       Impact factor: 5.994

9.  Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure.

Authors:  Wayne L Miller; Diane E Grill; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2013-08-05       Impact factor: 12.035

10.  Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.

Authors:  Amil M Shah; Sanjiv J Shah; Inder S Anand; Nancy K Sweitzer; Eileen O'Meara; John F Heitner; George Sopko; Guichu Li; Susan F Assmann; Sonja M McKinlay; Bertram Pitt; Marc A Pfeffer; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2013-11-18       Impact factor: 8.790

View more
  46 in total

1.  Error in Axis Label in Figures.

Authors: 
Journal:  JAMA Cardiol       Date:  2018-07-01       Impact factor: 14.676

Review 2.  Heart Failure With Preserved Ejection Fraction In Perspective.

Authors:  Marc A Pfeffer; Amil M Shah; Barry A Borlaug
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

3.  The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug
Journal:  Circ Res       Date:  2019-01-18       Impact factor: 17.367

4.  Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center.

Authors:  Hongyang Pi; Chad M Kosanovich; Adam Handen; Michael Tao; Jacqueline Visina; Gabrielle Vanspeybroeck; Marc A Simon; Michael G Risbano; Aken Desai; Michael A Mathier; Belinda N Rivera-Lebron; Quyen Nguyen; Jennifer Kliner; Mehdi Nouraie; Stephen Y Chan
Journal:  Chest       Date:  2020-02-25       Impact factor: 9.410

Review 5.  Evaluation and classification of pulmonary arterial hypertension.

Authors:  Sandeep Sahay
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

6.  The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.

Authors:  Masaru Obokata; Garvan C Kane; Yogesh N V Reddy; Vojtech Melenovsky; Thomas P Olson; Petr Jarolim; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

Review 7.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

Review 8.  Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.

Authors:  Sanjiv J Shah; Barry A Borlaug; Dalane W Kitzman; Andrew D McCulloch; Burns C Blaxall; Rajiv Agarwal; Julio A Chirinos; Sheila Collins; Rahul C Deo; Mark T Gladwin; Henk Granzier; Scott L Hummel; David A Kass; Margaret M Redfield; Flora Sam; Thomas J Wang; Patrice Desvigne-Nickens; Bishow B Adhikari
Journal:  Circulation       Date:  2020-03-23       Impact factor: 29.690

Review 9.  Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week.

Authors:  Bradley A Maron; Gabor Kovacs; Anjali Vaidya; Deepak L Bhatt; Rick A Nishimura; Susanna Mak; Marco Guazzi; Ryan J Tedford
Journal:  J Am Coll Cardiol       Date:  2020-12-01       Impact factor: 24.094

10.  Altered Hemodynamics and End-Organ Damage in Heart Failure: Impact on the Lung and Kidney.

Authors:  Frederik H Verbrugge; Marco Guazzi; Jeffrey M Testani; Barry A Borlaug
Journal:  Circulation       Date:  2020-09-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.